Table 3.

Pathological and clinical tumor response

Efficacy	TCH (N=39)	XEC-XT (N=33)	FEC-T (N=32)	TEC (N=35)	P-value
pCR	10 (25.6%)	6 (18.2%)	2 (6.3%)	7 (20%)	0.041
PR	24 (61.5%)	20 (60.6%)	18 (56.2%)	19 (54.3%)	0.784
SD	5 (12.8%)	7 (21.2%)	10 (31.3%)	9 (25.7%)	0.102
PD	0 (0%)	0 (0%)	2 (6.2%)	0 (0%)	0.136
ORR	34 (87.1%)	26 (78.7%)	20 (62.5%)	26 (74.3%)	0.107

Note: P-value by chi-squared test or Fisher’s exact test when the cell expectation was less than six.

Abbreviations: pCR, pathological complete response; PD, progressive disease; PR, partial response; ORR, objective remission rate; SD, stable disease; FEC, 5-fluorouracil/epirubicin/cyclophosphamide; TCH, docetaxel, carboplatin and trastu-zumab; TEC, docetaxel, epirubicin and cyclophosphamide; XEC, capecitabine/epirubicin/cyclophosphamide.